Epoch Investment Partners Inc. boosted its stake in shares of Petmed Express Inc (NASDAQ:PETS) by 71.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 857,722 shares of the company’s stock after acquiring an additional 357,304 shares during the period. Epoch Investment Partners Inc. owned 4.15% of Petmed Express worth $28,313,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the business. Renaissance Technologies LLC lifted its holdings in Petmed Express by 5.8% during the 3rd quarter. Renaissance Technologies LLC now owns 1,748,415 shares of the company’s stock worth $57,715,000 after buying an additional 96,215 shares during the period. JPMorgan Chase & Co. lifted its holdings in Petmed Express by 688.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 58,130 shares of the company’s stock worth $1,919,000 after buying an additional 50,756 shares during the period. GSA Capital Partners LLP lifted its holdings in Petmed Express by 193.0% during the 3rd quarter. GSA Capital Partners LLP now owns 35,451 shares of the company’s stock worth $1,170,000 after buying an additional 23,351 shares during the period. Stevens Capital Management LP acquired a new position in Petmed Express during the 3rd quarter worth about $405,000. Finally, Canada Pension Plan Investment Board lifted its holdings in Petmed Express by 17.7% during the 3rd quarter. Canada Pension Plan Investment Board now owns 92,400 shares of the company’s stock worth $3,050,000 after buying an additional 13,900 shares during the period. Hedge funds and other institutional investors own 95.11% of the company’s stock.
In other news, Director Robert C. Schweitzer sold 7,500 shares of Petmed Express stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $37.00, for a total value of $277,500.00. Following the completion of the transaction, the director now directly owns 88,334 shares of the company’s stock, valued at approximately $3,268,358. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.70% of the company’s stock.
PETS stock opened at $22.42 on Friday. Petmed Express Inc has a 1-year low of $22.11 and a 1-year high of $57.80. The stock has a market capitalization of $484.18 million, a PE ratio of 11.26 and a beta of 0.79.
Petmed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, October 22nd. The company reported $0.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.02. Petmed Express had a return on equity of 35.53% and a net margin of 14.88%. The firm had revenue of $71.40 million during the quarter, compared to analyst estimates of $71.93 million. During the same period last year, the company posted $0.43 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 16th. Stockholders of record on Monday, November 5th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 4.82%. The ex-dividend date of this dividend was Friday, November 2nd.
Several brokerages have commented on PETS. BidaskClub downgraded Petmed Express from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. ValuEngine raised Petmed Express from a “strong sell” rating to a “sell” rating in a report on Monday, August 20th. Finally, TheStreet downgraded Petmed Express from a “b” rating to a “c+” rating in a report on Thursday, November 29th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $42.67.
Petmed Express Company Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Featured Story: Growth Stocks
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.